BMY - Bristol-Myers Squibb Company

NYSE - NYSE Delayed Price. Currency in USD
53.94
-0.31 (-0.57%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close54.25
Open54.18
Bid0.00 x 800
Ask0.00 x 1400
Day's Range53.49 - 54.39
52 Week Range49.96 - 70.05
Volume5,844,160
Avg. Volume8,924,106
Market Cap88.167B
Beta1.06
PE Ratio (TTM)96.15
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.60 (2.92%)
Ex-Dividend Date2018-07-05
1y Target EstN/A
Trade prices are not sourced from all markets
  • What You Must Know About Bristol-Myers Squibb Company’s (NYSE:BMY) 7.31% ROE
    Simply Wall St.19 hours ago

    What You Must Know About Bristol-Myers Squibb Company’s (NYSE:BMY) 7.31% ROE

    This article is intended for those of you who are at the beginning of your investing journey and want to better understand how you can grow your money by investingRead More...

  • NYSE Pharma And Biotech Dividend Stock Picks
    Simply Wall St.2 days ago

    NYSE Pharma And Biotech Dividend Stock Picks

    Regularly affected by the ever-changing regulatory environment, the pharmaceutical and biotech industry is not one for producing the most stable cash flow. Thus, investors don’t usually associate this industry withRead More...

  • Bristol-Myers Posts Data on Empliciti, China Approves Opdivo
    Zacks3 days ago

    Bristol-Myers Posts Data on Empliciti, China Approves Opdivo

    Bristol-Myers (BMY) announces positive results on oncology drug Empliciti. The company's blockbuster drug, Opdivo, was also approved in China for lung cancer.

  • TheStreet.com4 days ago

    Eight Stocks That Are Poised to Change Direction

    Below is a list of names for those charts we believe are showing technical characteristics of either bullish or bearish reversal patterns that occurred over the past week. Bullish reversals imply institutional accumulation and the potential for higher prices.

  • Investopedia4 days ago

    5 Drug Stocks With Fat Payouts

    Big Pharma is struggling to keep up with the rest of the market this year as tepid revenue, growth, the expiration of key patents, and the likelihood of the government imposing tighter cost controls hold back its performance prospects. Earlier this month, while the broader S&P 500 was yielding just 2%, the dividend yield on the big drug companies in the index was nearly a full percentage point higher at 2.9%.

  • Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
    Motley Fool7 days ago

    Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers

    These two small biotechs with promising NASH drugs could attract several big suitors.

  • Does Bristol-Myers Squibb Company’s (NYSE:BMY) PE Ratio Signal A Selling Opportunity?
    Simply Wall St.9 days ago

    Does Bristol-Myers Squibb Company’s (NYSE:BMY) PE Ratio Signal A Selling Opportunity?

    Bristol-Myers Squibb Company (NYSE:BMY) is currently trading at a trailing P/E of 94.7x, which is higher than the industry average of 23.7x. Although some investors may jump to the conclusionRead More...

  • Fred Hutch leases iconic Lake Union Steam Plant facility
    American City Business Journals11 days ago

    Fred Hutch leases iconic Lake Union Steam Plant facility

    The Hutch leased more than 100,000 square feet of space in the facility, bringing the cancer research center's South Lake Union footprint to 1.44 million square feet.

  • The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie
    Zacks11 days ago

    The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie

    The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie

  • Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant
    Zacks14 days ago

    Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant

    Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.

  • See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
    Markit14 days ago

    See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.

    Bristol-Myers Squibb Co NYSE:BMY

  • Why Nektar Therapeutics Stock Stumbled 11.8% Today
    Motley Fool14 days ago

    Why Nektar Therapeutics Stock Stumbled 11.8% Today

    Shares have been on a roller-coaster ride since the company presented updated study results for its latest drug and outlined its goals at an investor conference on Wednesday.

  • Here's Why Nektar Therapeutics Jumped as Much as 17% Today
    Motley Fool15 days ago

    Here's Why Nektar Therapeutics Jumped as Much as 17% Today

    The biopharma stock is bouncing after a wild week.

  • ASCO Ends: Winners & Losers at the Key Cancer Research Event
    Zacks16 days ago

    ASCO Ends: Winners & Losers at the Key Cancer Research Event

    The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

  • Nektar Therapeutics Stock Is a Buy After a Major Market Misread
    InvestorPlace17 days ago

    Nektar Therapeutics Stock Is a Buy After a Major Market Misread

    When it was last covered in mid-May, few biotech investors questioned the valuation and prospects for Nektar Therapeutics (NASDAQ:NKTR) as shares held the $80 level. Such a quick drop is typical for any stock that rose by more than four-fold in under a year, but in the case of Nektar, investors are misinterpreting the clinical results. Nektar Therapeutics’ nearly 42 percent drop on June 4 now implies a more than two-fold upside for investors.

  • Nektar (NKTR) and Bristol-Myers Present Data on Cancer Study
    Zacks17 days ago

    Nektar (NKTR) and Bristol-Myers Present Data on Cancer Study

    Nektar (NKTR) and Bristol-Myers Squibb announce preliminary data from the ongoing PIVOT phase I/II study evaluating the combination of Nektar's NKTR-214 with Bristol-Myers Squibb's Opdivo.

  • MarketWatch17 days ago

    Do Nektar’s disappointing clinical trial results invalidate $2 billion Bristol-Myers deal?

    The latest results from a collaboration testing Bristol-Myers Squibb’s cancer drug Opdivo with Nektar Therapeutics’ NKTR-214 didn’t exactly impress investors. Wall Street analysts described the phase 1/2 clinical trial data as “underwhelming” and “immature,” and Nektar (NKTR) shares plummeted 41.8 on Monday. Combination treatments that pair two cancer drugs in an effort to boost their effect are an important trend in cancer research right now.

  • Bristol-Myers (BMY) Reports Data from CheckMate-214 Study
    Zacks17 days ago

    Bristol-Myers (BMY) Reports Data from CheckMate-214 Study

    Bristol-Myers Squibb (BMY) announces encouraging data from the phase III CheckMate -214 study.

  • TheStreet.com17 days ago

    Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

    Shares plummeted after investors and Wall Street analysts found Nektar's mid-stage trial results for its collaborative effort with Bristol-Myers Squibb Co. to combine Nektar's NKTR-214 top immune-oncology program with Bristol-Myers' Opdivo drug to be below expectations. Response rates for patients with melanoma and kidney cancer patients decreased, according to the study that was released to the American Society of Clinical Oncology (ASCO) over the weekend.

  • Is Nektar Therapeutics Stock a Bargain Now?
    Motley Fool17 days ago

    Is Nektar Therapeutics Stock a Bargain Now?

    A highly anticipated presentation left investors with more questions than answers. Is the stock a bad-news buy?

  • CNBC17 days ago

    $15 billion biotech stock loses more than 40% of its value after skin cancer drug study falls short

    Nektar's market cap, which was over $15 billion by Friday's close, fell to $9 billion by Monday's close. The fall came after data released Saturday suggested patients diagnosed with melanoma aren't reacting to the company's experimental treatment as well as earlier samples did. Shares of biotech company Nektar Therapeutics NKTR lost nearly half their value Monday after the company gave a clinical trial update that fell well short of investor expectations.

  • Reuters18 days ago

    US STOCKS-Technology rally helps Wall Street push higher

    Technology stocks led the market higher on Monday as Apple and Microsoft boosted the sector after the iPhone maker kicked off its annual developers conference and the Windows software maker announced an acquisition. Apple unveiled its latest operating system iOS 12 at the conference and even after paring some gains in the afternoon, for a 0.8 percent gain, it still provided the biggest boost to the S&P 500 and helped take the Nasdaq close to its intraday record reached in mid-March.

  • InvestorPlace18 days ago

    Why Bristol-Myers Squibb Company Shares Are Down Today

    Bristol-Myers Squibb Company (NYSE:BMY) shares were declining Monday as the company joined forces with another company to develop a cancer drug that’s been disappointing so far. The result was underwhelming as Wall Street investors were not impressed by the end result. Analysts said that the phase 1/2 clinical trial data was “underwhelming” and “immature,” sending both stocks dropping early Monday.

  • Barrons.com18 days ago

    [$$] Nektar's 39% Drop: A New Record for a Volatile Stock

    Nektar Therapeutics shares plummeted 39% Monday morning after the San Francisco-based biotech company released disappointing clinical trial results over the weekend regarding its key product, NKTR-214. Tests showed that response rates in cancer patients treated with a combination of NKTR-214 and the Bristol-Myers Squibb (BMY) drug Opdivo declined from previous studies. “214 may not be adding an incremental benefit,” wrote Joshua Schimmer of Evercore ISI Research in a note today.

  • Why Nektar Therapeutics Shares Are Plunging Today
    InvestorPlace18 days ago

    Why Nektar Therapeutics Shares Are Plunging Today

    This study seeks to determine the effectiveness of combining Bristol-Myers Squibb Co (NYSE:BMY) Opdivo with Nektar Therapeutics NKTR-214. The clinical trail is specifically looking at treating patients with melanoma, renal cell, urothelial, non-small cell lung and triple negative breast cancers. The results included changes for three tumor types.